Nektar Therapeutics (NKTR) 15.45 $NKTR
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.40 (-0.01), ARLZ: 3.38 (+0.04), INFI: 1.30 (-0.02), NKTR: 15.45 (+0.36)
Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
PR Newswire - Mon Jun 06, 1:00PM CDT
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center. The new preclinical data presented demonstrate that treatment with single-agent NKTR-214 mobilizes tumor-killing T cells into colon cancer tumors. In addition, mouse pharmacodynamics data demonstrated that a single dose of NKTR-214 can increase and sustain STAT5 phosphorylation (a marker of IL-2 pathway activation) through one week post-dose. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7, 2016.
NKTR: 15.45 (+0.36)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City
PR Newswire - Thu Jun 02, 5:30PM CDT
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
NKTR: 15.45 (+0.36)
Nektar Therapeutics Announces Executive Management Promotions
PR Newswire - Thu Jun 02, 3:30PM CDT
Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President & Chief Financial Officer of Nektar. Mr. Nicholson has served as the Chief Financial Officer of Nektar since 2007. Mr. Labrucherie has served as Senior Vice President, General Counsel and Secretary of Nektar since 2007.
NKTR: 15.45 (+0.36)
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Nektar Therapeutics (NKTR) has entered an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald in Europe, Switzerland and Turkey.
ANIP: 56.01 (+3.22), PFE: 34.49 (+0.02), BMY: 72.33 (+0.02), NKTR: 15.45 (+0.36)
Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD(TM) (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases
PR Newswire - Wed Jun 01, 7:15AM CDT
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the BEACON study) in patients with advanced breast cancer. The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe (EEA), Switzerland and Turkey. Nektar Therapeutics will retain rights to ONZEALD in the United States and the rest of the world.
NKTR: 15.45 (+0.36)
Neos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer
GlobeNewswire - Tue May 31, 3:05PM CDT
Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it has appointed Juergen A. Martens, PhD, to the position of Chief Technology and Operations Officer.
NKTR: 15.45 (+0.36), NEOS: 9.60 (+0.19)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 41.78 (+1.56), SQNM: 1.11 (-0.01), TSRO: 44.89 (+2.42), NKTR: 15.45 (+0.36)
Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 179.80 (+4.42), AAVL: 4.14 (-0.18), NKTR: 15.45 (+0.36), REGN: 355.92 (+4.00)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 179.80 (+4.42), ICPT: 153.43 (+5.33), BIOD: 0.32 (-0.01), NKTR: 15.45 (+0.36)
Radius Health (RDUS) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:54PM CDT
Radius Health, Inc. (RDUS) posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents
RDUS: 36.94 (+1.27), SHPG: 179.80 (+4.42), BIOD: 0.32 (-0.01), NKTR: 15.45 (+0.36)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 58.63 (+1.95), ECYT: 3.40 (+0.08), SHPG: 179.80 (+4.42), NKTR: 15.45 (+0.36)
McKesson (MCK) Q4 Earnings Lag, Revenues Top Marginally
Zacks Equity Research - Zacks Investment Research - Thu May 05, 2:58PM CDT
McKesson Corporation (MCK) reported fourth-quarter fiscal 2016 (ended Mar 31, 2016) earnings of $2.44 per share, lower than both the Zacks Consensus Estimate of $3.01 and the year-ago figure of $2.94.
MCK: 183.25 (+1.72), SHPG: 179.80 (+4.42), NKTR: 15.45 (+0.36), RAD: 7.79 (+0.06)
Why Nektar Therapeutics Inc Is Dropping Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed May 04, 3:53PM CDT
Image source: Images_of_Money via Flickr Creative Commons. What: Shareholders of Nektar Therapeutics are having a bit of a rough day; the company's stock has dropped more than 10% as of 3:45 p.m. ET today after investors got a good look at the...
AZN: 29.17 (+0.47), BXLT: 46.02 (-0.18), NKTR: 15.45 (+0.36)
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 12.63 (+0.02), AZN: 29.17 (+0.47), BXLT: 46.02 (-0.18), NKTR: 15.45 (+0.36)
Nektar Therapeutics Has Returned 9.6% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed May 04, 1:50PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 11th, 2016 at $12.56. In approximately 2 months, Nektar Therapeutics has returned 9.60% as of today's recent price of $13.76.
NKTR: 15.45 (+0.36)
Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 179.80 (+4.42), PRTA: 40.11 (+1.94), NKTR: 15.45 (+0.36)
Nektar Therapeutics Reports Financial Results for the First Quarter of 2016
PR Newswire - Tue May 03, 3:05PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016.
NKTR: 15.45 (+0.36)
Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets
PR Newswire - Thu Apr 28, 7:00AM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2016, on Tuesday, May 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
NKTR: 15.45 (+0.36)
29.9% Return Seen to Date on SmarTrend Nektar Therapeutics Call (NKTR)
Comtex SmarTrend(R) - Wed Apr 27, 1:32PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 11th, 2016 at $12.56. In approximately 2 months, Nektar Therapeutics has returned 29.87% as of today's recent price of $16.31.
NKTR: 15.45 (+0.36)
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.40 (-0.01), ARLZ: 3.38 (+0.04), INFI: 1.30 (-0.02), NKTR: 15.45 (+0.36)
Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
PR Newswire - Mon Jun 06, 1:00PM CDT
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center. The new preclinical data presented demonstrate that treatment with single-agent NKTR-214 mobilizes tumor-killing T cells into colon cancer tumors. In addition, mouse pharmacodynamics data demonstrated that a single dose of NKTR-214 can increase and sustain STAT5 phosphorylation (a marker of IL-2 pathway activation) through one week post-dose. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7, 2016.
NKTR: 15.45 (+0.36)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City
PR Newswire - Thu Jun 02, 5:30PM CDT
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
NKTR: 15.45 (+0.36)
Nektar Therapeutics Announces Executive Management Promotions
PR Newswire - Thu Jun 02, 3:30PM CDT
Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President & Chief Financial Officer of Nektar. Mr. Nicholson has served as the Chief Financial Officer of Nektar since 2007. Mr. Labrucherie has served as Senior Vice President, General Counsel and Secretary of Nektar since 2007.
NKTR: 15.45 (+0.36)
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Nektar Therapeutics (NKTR) has entered an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald in Europe, Switzerland and Turkey.
ANIP: 56.01 (+3.22), PFE: 34.49 (+0.02), BMY: 72.33 (+0.02), NKTR: 15.45 (+0.36)
Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD(TM) (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases
PR Newswire - Wed Jun 01, 7:15AM CDT
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the BEACON study) in patients with advanced breast cancer. The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe (EEA), Switzerland and Turkey. Nektar Therapeutics will retain rights to ONZEALD in the United States and the rest of the world.
NKTR: 15.45 (+0.36)
Neos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer
GlobeNewswire - Tue May 31, 3:05PM CDT
Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it has appointed Juergen A. Martens, PhD, to the position of Chief Technology and Operations Officer.
NKTR: 15.45 (+0.36), NEOS: 9.60 (+0.19)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 41.78 (+1.56), SQNM: 1.11 (-0.01), TSRO: 44.89 (+2.42), NKTR: 15.45 (+0.36)
Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 179.80 (+4.42), AAVL: 4.14 (-0.18), NKTR: 15.45 (+0.36), REGN: 355.92 (+4.00)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 179.80 (+4.42), ICPT: 153.43 (+5.33), BIOD: 0.32 (-0.01), NKTR: 15.45 (+0.36)
Radius Health (RDUS) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:54PM CDT
Radius Health, Inc. (RDUS) posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents
RDUS: 36.94 (+1.27), SHPG: 179.80 (+4.42), BIOD: 0.32 (-0.01), NKTR: 15.45 (+0.36)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 58.63 (+1.95), ECYT: 3.40 (+0.08), SHPG: 179.80 (+4.42), NKTR: 15.45 (+0.36)
McKesson (MCK) Q4 Earnings Lag, Revenues Top Marginally
Zacks Equity Research - Zacks Investment Research - Thu May 05, 2:58PM CDT
McKesson Corporation (MCK) reported fourth-quarter fiscal 2016 (ended Mar 31, 2016) earnings of $2.44 per share, lower than both the Zacks Consensus Estimate of $3.01 and the year-ago figure of $2.94.
MCK: 183.25 (+1.72), SHPG: 179.80 (+4.42), NKTR: 15.45 (+0.36), RAD: 7.79 (+0.06)
Why Nektar Therapeutics Inc Is Dropping Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed May 04, 3:53PM CDT
Image source: Images_of_Money via Flickr Creative Commons. What: Shareholders of Nektar Therapeutics are having a bit of a rough day; the company's stock has dropped more than 10% as of 3:45 p.m. ET today after investors got a good look at the...
AZN: 29.17 (+0.47), BXLT: 46.02 (-0.18), NKTR: 15.45 (+0.36)
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 12.63 (+0.02), AZN: 29.17 (+0.47), BXLT: 46.02 (-0.18), NKTR: 15.45 (+0.36)
Nektar Therapeutics Has Returned 9.6% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed May 04, 1:50PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 11th, 2016 at $12.56. In approximately 2 months, Nektar Therapeutics has returned 9.60% as of today's recent price of $13.76.
NKTR: 15.45 (+0.36)
Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 179.80 (+4.42), PRTA: 40.11 (+1.94), NKTR: 15.45 (+0.36)
Nektar Therapeutics Reports Financial Results for the First Quarter of 2016
PR Newswire - Tue May 03, 3:05PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016.
NKTR: 15.45 (+0.36)
Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets
PR Newswire - Thu Apr 28, 7:00AM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2016, on Tuesday, May 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
NKTR: 15.45 (+0.36)
29.9% Return Seen to Date on SmarTrend Nektar Therapeutics Call (NKTR)
Comtex SmarTrend(R) - Wed Apr 27, 1:32PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 11th, 2016 at $12.56. In approximately 2 months, Nektar Therapeutics has returned 29.87% as of today's recent price of $16.31.
NKTR: 15.45 (+0.36)
